Popular on EntSun
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1 - 330
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 253
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 209
- Touch Massage London Unveils Premium Local Massage Services to Transform Wellbeing Across the Capital - 149
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide - 139
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology - 138
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 137
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick - 136
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform - 135
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 128
Similar on EntSun
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- Java Holdings LLC Acquires +Peptide, Expanding Portfolio Across Coffee, Science, and Functional Nutrition
- OneSolution® Expands to Orlando with New Altamonte Springs Implant Center
- 2025: A Turning Point for Human Rights. CCHR Demands End to Coercive Psychiatry
- A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
NETRF Awards Ten Groundbreaking Research Grants to Advance Neuroendocrine Cancer Treatment
EntSun News/11049288
BOSTON - EntSun -- The Neuroendocrine Tumor Research Foundation (NETRF) today announced its newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising scientific approaches to
understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2
million, bringing NETRF's all-time investment in research to $39.8 million.
"As the largest global funder of neuroendocrine cancer research, NETRF is the lifeline for
dedicated scientists working tirelessly to unravel the complexities of this uncommon and
challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and
personalized treatments. With this crucial funding, we're not just advancing science—we're
paving the way to a future without neuroendocrine cancer," she said.
The new awardees will focus on these themes in neuroendocrine cancer research:
More on EntSun News
● Discovering the origins of neuroendocrine cancer and causes of disease progression
● Investigating new molecular targets for treatment
● Identifying novel approaches to combat drug resistance to existing treatments
● Studying a novel blood biomarker as a tool for earlier detection
● Improving the safety and effectiveness of alpha-particle radioligand therapy
In this new group of grantees, NETRF is funding six Investigator Awards, two Pilot Awards and two Mentored Research Awards, all focusing on basic and translational science. Six of the 10 awardees are first-time grant recipients of NETRF. The grant recipients are selected through a competitive and rigorous scientific peer-review process.
Academic institutions receiving NETRF funding include The University of Texas MD Anderson
Cancer Center, The University of Texas Health Science Center at Houston, University of Iowa
Health Care, Laval University in Quebec, Massachusetts General Hospital, Korea Military
Academy, Dana-Farber Cancer Institute, Stanford University School of Medicine, and UCLA
More on EntSun News
David Geffen School of Medicine.
Since its founding in 2005, NETRF has provided funding for 156 research projects at 76
institutions in 17 countries worldwide.
"Our role of building and nurturing the neuroendocrine cancer research community is vital.
NETRF is often the sole source of funding for early-career scientists with groundbreaking
ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the
innovative researchers we've funded are making important discoveries that will have positive
impacts on the patient community."
Gellerman thanked the many individuals and foundations whose financial gifts support NETRF's research and education programs, including generous funding from The Carol DeBacker Charitable Trust, the Martha O'Donnell Pagel Fund for Rare Cancer Research, Karpus Family Foundation, Jim Rodin, Laura and Lew Moorman, and Katherine's Light Foundation.
NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support. https://www.NETRF.org
understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2
million, bringing NETRF's all-time investment in research to $39.8 million.
"As the largest global funder of neuroendocrine cancer research, NETRF is the lifeline for
dedicated scientists working tirelessly to unravel the complexities of this uncommon and
challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and
personalized treatments. With this crucial funding, we're not just advancing science—we're
paving the way to a future without neuroendocrine cancer," she said.
The new awardees will focus on these themes in neuroendocrine cancer research:
More on EntSun News
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- The New Monaco of the South (of Italy)
- Producer 9-0 Opens the "Digital Vault," Partners W/20 Artists to Finish Long-Delayed Projects
- Producer 9-0 Partners With 20 New Artists to Launch Global Wave of Music Under No Limit Forever East
- Upcoming Movies: 360 Sound And Vision Releases It's Slate Of Movies For 2026
● Discovering the origins of neuroendocrine cancer and causes of disease progression
● Investigating new molecular targets for treatment
● Identifying novel approaches to combat drug resistance to existing treatments
● Studying a novel blood biomarker as a tool for earlier detection
● Improving the safety and effectiveness of alpha-particle radioligand therapy
In this new group of grantees, NETRF is funding six Investigator Awards, two Pilot Awards and two Mentored Research Awards, all focusing on basic and translational science. Six of the 10 awardees are first-time grant recipients of NETRF. The grant recipients are selected through a competitive and rigorous scientific peer-review process.
Academic institutions receiving NETRF funding include The University of Texas MD Anderson
Cancer Center, The University of Texas Health Science Center at Houston, University of Iowa
Health Care, Laval University in Quebec, Massachusetts General Hospital, Korea Military
Academy, Dana-Farber Cancer Institute, Stanford University School of Medicine, and UCLA
More on EntSun News
- Waliin Completes First Community Fundraising Round and Unveils Major Platform Expansion
- Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
- Is Rolex the Best Watch Ever Made? Experts Weigh In
- Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
- PowerTribe Releases New Heavy Metal Single "The Earthlings Have Died"
David Geffen School of Medicine.
Since its founding in 2005, NETRF has provided funding for 156 research projects at 76
institutions in 17 countries worldwide.
"Our role of building and nurturing the neuroendocrine cancer research community is vital.
NETRF is often the sole source of funding for early-career scientists with groundbreaking
ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the
innovative researchers we've funded are making important discoveries that will have positive
impacts on the patient community."
Gellerman thanked the many individuals and foundations whose financial gifts support NETRF's research and education programs, including generous funding from The Carol DeBacker Charitable Trust, the Martha O'Donnell Pagel Fund for Rare Cancer Research, Karpus Family Foundation, Jim Rodin, Laura and Lew Moorman, and Katherine's Light Foundation.
NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support. https://www.NETRF.org
Source: Neuroendocrine Tumor Research Foundation
Filed Under: Health
0 Comments
Latest on EntSun News
- Dugan Air Donates $10,000 to Indian Creek Schools
- The Best And Worst Of Entertainment In 2025 Revealed
- Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
- Indie Film Marries Arthouse Aesthetics to Fantasy While Tackling Themes of Humanity and the Ecology
- 2025: A Turning Point for Human Rights. CCHR Demands End to Coercive Psychiatry
- The 22% Tax Reality: Finland's New Gambling Law Creates a "Fiscal Trap" for Grey Market Casino Players
- Streaming Industry Consultant Marc Rashba Joins BayView and DotStudioPro to Bolster Content Reach
- Holiday Comedy A Boyfriend For Christmas Wins Over Audiences with Laughs, Heart — and a Twist
- Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
- TIA LYNN — a new direction, a higher level. 2026 it's up
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion
- Golden Paper Launches a New Chapter in Its Americas Strategy- EXPOPRINT Latin America 2026 in Brazil
- Historic 327-Acre Waterfront Estate to Be Won Through Public Raffle in the U.S
- Comedy Musical Shangri-La-La-La Enters Next Development Phase with an 1-hour version
- UK Financial Ltd Executes Compliance Tasks Ahead Of First-Ever ERC-3643 Exchange-Traded Token, SMCAT & Sets Date For Online Investor Governance Vote
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder
- TheOneLofi2: New Home for Chill Lo-Fi Hip Hop Beats Launches on YouTube
- ZEELOOL's Best Women's Eyeglasses Styles for 2026
- eJoule Inc Participates in Silicon Dragon CES 2026
- Oliver Sean's "Everyday Will Be Like A Holiday" Featuring the Real Indie Project Hits #1 in Portugal on Christmas Eve